reason report
bottom line remain outperform agil given lead
posit chemic energi end-market maintain
well-diversifi posit across healthcar growth market
pharma lst diagnost agil report deliv
roughli in-lin result organ revenu ep
expect stock trade-off given higher expect head
quarter higher expect expens recent
acquir lasergen us agil becom
top-lin growth stori long-term number new product includ
ultivo intuvo link gain share upsid like higher
growth lasergen launch aati drive accret near-
term link reduc pt expect higher
expens lasergen acquisit drive lower earn reflect
model
impact china food agenc reorgan appear
transitori sale return back agil agil lost
sale quarter china expect lose anoth
due reorgan multipl food agenc nmsa nation
market supervis administr chines govern
view sale return back earlier agil
continu maintain lead posit china given legaci
posit sale account food test revenu
world-wide among agil peer expect op lesser
extent op come pressur china food agenc
icp-m top-lin miss revenu
made icp-m type mass spectromet
detect presenc metal environment monitor applic
water sourc environment monitor deliv
growth vs expect categori due number icp-
ms ship quarter close result believ
revenu book project organ growth
remain roughli revis project howev
slightli lower ep back
higher expens lasergen acquisit took place earlier
year
life scienc tool diagnost
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
dilut impact lasergen like stay investor mind
agil post anoth solid quarter agil acquir
lasergen share recent commit path launch diagnost
sequenc till agil invest
 limit hope major adjust
oper margin upsid next year believ agil
manag still maintain highli conserv guid year
suggest potenti upsid current estim
agil host analyst day june new york citi
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium long-term spin-off keysight
electron manag busi becom pure-play life scienc tool lst
compani agil focus deliv adjust oper margin
believ achiev exceed longer term leadership ceo mcmullen
agil compet aggress multipl market deliv solid growth biopharma
sale maintain either posit across end-market
includ food environment chemical/energi emerg market includ china
continu post double-digit growth agil posit capit given sizabl exposur
geographi intuvo product cycl could repres opportun
current under-appreci agil repres compani develop core root
industri chemic electron market year transform life
scienc tool technolog leader diversifi access lead end-market
agil share current trade ev/ebitda in-lin life scienc
tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
price target lower appli premium averag
lst group ev/ebitda multipl premium earlier
result appli ev/ebitda multipl ebitda estim given
number tailwind posit agil better compar lst peer group
continu exposur robust biopharma growth china demand believ premium
warrant sustain
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
routin tradit analysi
limit growth declin market
servic contract aftermarket
wide use
quantit
peptid
analysi small
mab refer monoclon antibodi drug biotherapeut
figur china revenu exposur within lst univers
compani file leerink partner base revenu
